Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AYIFER-XT
- Development stage
- Unknown
- Lead developer
- Makshi Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AYIFER-XT is a combination pharmaceutical product marketed by Makshi Healthcare, containing ferrous ascorbate, folic acid, and zinc sulphate. It is primarily used as a hematinic to treat and prevent iron deficiency anemia, particularly in high-demand states such as pregnancy and lactation. Ferrous ascorbate is a synthetic molecule of ascorbic acid and ferrous iron, which offers superior absorption and better gastrointestinal tolerance compared to traditional iron salts. Folic acid is essential for DNA synthesis and the prevention of neural tube defects, while zinc acts as a vital cofactor for various enzymes involved in cellular metabolism and immune function.
- Brand names
- AYIFER-XT
02
Targets
DHFR (Dihydrofolate reductase)SLC11A2 (DMT1)SLC39A4 (Zinc transporter ZIP4)DNA
Beyond the preview
Go deeper on AYIFER-XT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AYIFER-XT.